The copper chelator tetrathiomolybdate (TTM) treatment hinders breast cancer metastasis by lowering Cu2+ levels and suppressing Mediator Of Cell Motility 1 (MEMO1) expression and angiogenesis [34]. The gene discussed is MEMO1; the disease is breast carcinoma.